Ionis Pharmaceuticals Inc (IONS)

[Bio_pete]

ISIS's technology is still not respected even after this remarkable deal. It just shows how lazy most biotech investors are. ISIS has a number of important drugs in development, collaborations, and the IBIS division could be huge.

You could not have asked for a better deal. $375 million upfront with $1.5 billion in additional milestone payments & royalties. The company will never have to raise another dollar or dilute.

I was hoping for a buy-out, but a GENZ collaboration is the next best thing. Positive analyst/investor conference after the close.

$40 stock in a year.

Congrats.